NeuroSense Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de NeuroSense Therapeutics de 46.3% y 70% respectivamente, mientras que el BPA crecerá en un 51.8% al año.

Información clave

46.3%

Tasa de crecimiento de los beneficios

51.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	70.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	11 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Jul 06

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

Jun 30

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

Mar 31

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

Mar 22

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

Dec 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NRSN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	11	-10	N/A	N/A	1
12/31/2025	N/A	-13	N/A	N/A	1
12/31/2024	N/A	-10	N/A	N/A	1
6/30/2024	N/A	-10	-10	-10	N/A
3/31/2024	N/A	-13	N/A	N/A	N/A
12/31/2023	N/A	-10	-8	-8	N/A
9/30/2023	N/A	-11	N/A	N/A	N/A
6/30/2023	N/A	-11	-7	-7	N/A
3/31/2023	N/A	-14	N/A	N/A	N/A
12/31/2022	N/A	-10	-8	-8	N/A
9/30/2022	N/A	-9	N/A	N/A	N/A
6/30/2022	N/A	-7	-5	-5	N/A
3/31/2022	N/A	-5	N/A	N/A	N/A
12/31/2021	N/A	-3	-2	-2	N/A
9/30/2021	N/A	-5	N/A	N/A	N/A
6/30/2021	N/A	-5	-1	-1	N/A
3/31/2021	N/A	-5	N/A	N/A	N/A
12/31/2020	N/A	-3	-1	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NRSN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NRSN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NRSN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que NRSN no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que NRSN no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NRSN se prevé que sea elevada dentro de 3 años.

NeuroSense Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

NeuroSense Therapeutics Ltd. Advances Plans for Early Commercialization of ALS Treatment in Canada

Neurosense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

New major risk - Share price stability

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Ltd. has filed a Follow-on Equity Offering in the amount of $2.524437 million.

NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding

NeuroSense Therapeutics Ltd. Announces Positive Biomarker Data from ALS Phase 2B Clinical Trial

NeuroSense Therapeutics Ltd. Announces Additional Positive Results from its 12-Month PARADIGM Phase 2b Study of PrimeC in ALS Patients

NeuroSense Therapeutics Ltd. Reports Statistically Significant Results from the 12-Month Paradigm Study Evaluating PrimeC in People Living with Amyotrophic Lateral Sclerosis

New major risk - Shareholder dilution

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 27, 2024

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding

NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial

Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

New major risk - Share price stability

New major risk - Revenue and earnings growth

Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness

Neurosense Therapeutics Ltd. Announces Results of Non-Sponsored in Vitro Study of PrimeC in Amyotrophic Lateral Sclerosis

European Medicines Agency Grants the Small and Medium-Sized Enterprise Status of Neurosense Therapeutics Ltd

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

High number of new and inexperienced directors

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics Ltd. Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

NeuroSense Therapeutics Ltd. Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics Ltd. Receives Regulatory Approval to Commence Patient Enrollment in Italy for Its Phase 2B Trial in Als

Neurosense Receives FDA Clearance of IND for Its ALS Phase 2b Study

Less than half of directors are independent

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

Neurosense Therapeutics Ltd. Announces Positive Primec Toxicology Data Supportive of Current Phase IIb Paradigm Als Clinical Trial

NeuroSense Therapeutics GAAP EPS of -$0.55

NeuroSense Therapeutics Ltd. Reports Strong Patient Enrollment in Its Phase IIb PARADIGM Trial for Its Lead Drug Candidate PrimeC for the Treatment of ALS

NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Neurosense Therapeutics Ltd. Reports Completion of the "In-Life" Phase of Its 90-Day Glp Toxicology Study Successfully

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

NeuroSense Therapeutics Ltd. Reports Positive Results from Stage III ALS Biomarker Study

NeuroSense Therapeutics Ltd. Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 21, 2022